New Enterprise Associates related stories
All articles and analysis
Executive moves, week of Jan. 18, 2010Hires and promotions at Elevation, Macquarie and other VC and PE firms
- Week in deals, Jan. 18. 2010
Summary of North American tech companies and other startups that raised venture financing in the past week
- NVCA confirms: It was a bad year for fund-raising
Despite 4Q increase, 2009 was worst year for committing dollars to VC since 2003
- Venture Capital: Who (Not What) Is Broken
Reports of venture capital’s demise are greatly exaggerated. Not a day goes by without a commentator reading the VC industry its last rites. And many of the gloomiest prognostications come from those inside the industry. A recent survey /60650/is-the-venture-capital-business-broken/ found that 53% of VC respondents felt the industry was broken. It’s too easy and lazy (and self-serving for some) to claim the VC model as broken. Nineties nostalgia recalls VC as an investment strategy played on Lake Wobegon, where the sun always shined, all portfolio companies were above average, prices always moved higher and everyone came away a winner.
- CalPERS Doc Dump H - Z
CalPERS has just released a ton of docs related to placement agents used by their general partners. We're uploading them below- There are literally hundreds. Help us read through them for interesting items. Placement agent disclosure release /wp-content/uploads//placement-agent-disclosure-2010-final-release.doc Placement agent compensation /wp-content/uploads//placement-agent_compensation-jan-13.xls We're posting the second half below; read the first half here /60825/calpers-docs-a-f/
- Not all chip backers feeling the blues
Investors expect a growth spurt in semiconductors, driven by consumer electronics
- VC fund briefs, week of Jan. 11, 2010
News briefs about venture firms Flywheel, NEA and Almaz Capital
- Week in deals, Jan. 11, 2010
Summary of North American tech companies and other startups that raised venture financing in the past week
- Phase Bioscience Raises $25 Million
Phase Bioscience Inc., a Durham, N.C.-based developer of therapeutic fusion proteins, has raised$25 million in new Series B funding. New Enterprise Associates and a unit of OSI Pharmaceuticals were joined by return backers Hatteras Venture Partners, Johnson & Johnson Development Corp. and Fletcher Spaght Ventures. The company previously raised around $6.8 million.